$1.70
NASDAQ:
RENB
-0.27 ( -13.71% )
Pricing delayed by 20 minutes
Last updated: 25/04/2024 16:00 EST
RENOVARO CUBE
Renovaro Cube is commited to the early detection of cancer, to intervene at a stage where treatment can be most effective. We are pioneering a multi-modal approach for the early detection of cancer and its recurrence involving blood biopsies, imaging and multi-omics analysis.
For more information on Renovaro Cube, go to their website at renovarocube.com
RENOVARO BIO
Renovaro Biosciences, Inc. has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.
For more information on Renovaro Biosciences, go to their website at renovarobio.com
News Items
April 24, 2024
RenovaroCube to Acquire 100% Ownership of Cyclomics
RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.
April 18, 2024
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board
This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
February 14, 2024
Statement of Renovaro Inc
We felt compelled to comment on the shorter Hindenburg’s opinion piece.
February 13, 2024
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Information request form
Your inquiries matter. Feel free to use the form below to get in touch, and our team will make it a priority to respond as quickly as possible.
a future free from toxic chemotherapy